211308-82-6

Basic information

• Product Name: 3-iodo-5-(trifluoromethyl)-2-pyridinylamine
• Synonyms: 2-Amino-3-iodo-5-(trifluoromethyl)-pyridine;3-Iodo-5-trifluoroMethyl-pyridin-2-ylaMine;-iodo-5-(trifluoromethyl)-2-pyridinylamine;2-Pyridinamine, 3-iodo-5-(trifluoromethyl)-;3-iodo-5-(trifluoromethyl)-2-pyridinylamine;3-IODO-5-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE;3-Iodo-5-(trifluoromethyl)-2-pyridinylamine(en)
• CAS NO: 211308-82-6
• Molecular Formula: C₆H₄F₃IN₂
• Molecular Weight: 288.01
• Product Categories: amine|alkyl bromide
• Mol File: 211308-82-6.mol

Chemical Properties

• Melting Point: 97-98°
• Boiling Point: 269.4°C at 760 mmHg
• Flash Point: 116.7°C
• Appearance: /
• Density: 2.049g/cm³
• Vapor Pressure: 0.00728mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-iodo-5-(trifluoromethyl)-2-pyridinylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-iodo-5-(trifluoromethyl)-2-pyridinylamine(211308-82-6)
• EPA Substance Registry System: 3-iodo-5-(trifluoromethyl)-2-pyridinylamine(211308-82-6)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 211308-82-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-iodo-5-(trifluoromethyl)-2-pyridinylamine serves as a synthetic building block, playing a crucial role in the development of new pharmaceuticals. Its presence in molecular structures can enhance the pharmacological profile of drugs, potentially leading to improved therapeutic effects.
Used in Organic Synthesis:
In the realm of organic synthesis, 3-iodo-5-(trifluoromethyl)-2-pyridinylamine is utilized as a key intermediate. Its unique structural features facilitate the creation of a variety of complex organic molecules, which can be further employed in various chemical and material applications.
Used in Agrochemicals:
3-iodo-5-(trifluoromethyl)-2-pyridinylamine has also been investigated for its potential as an intermediate in the synthesis of agrochemicals. Its incorporation into these compounds may lead to the development of novel products with enhanced efficacy in agricultural settings.
The iodine and trifluoromethyl groups present in 3-iodo-5-(trifluoromethyl)-2-pyridinylamine are particularly noteworthy, as they can significantly influence the reactivity, stability, and biological activity of the molecules in which 3-iodo-5-(trifluoromethyl)-2-pyridinylamine is a part, making it a valuable asset in the synthesis of pharmaceuticals and agrochemicals.

InChI:InChI=1/C6H4F3IN2/c7-6(8,9)3-1-4(10)5(11)12-2-3/h1-2H,(H2,11,12)

Upstream product

• 74784-70-6 2-amino-5-trifluoromethylpyridine 
• 1002916-67-7 N-(3-iodo-5-(trifluoromethyl)pyridin-2-yl)pivalamide 

Downstream Products

• 1211514-97-4 2-amino-3-cyano-5-trifluoromethylpyridine 
• 1036027-52-7 5-(trifluoromethyl)-3-((trimethylsilyl)ethynyl)pyridin-2-amine 
• 1420885-78-4 N-(3-{[2-(4-fluorophenyl)-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino]methyl}pyridin-2-yl)-N-methylmethanesulfonamide 
• 1420885-79-5 2-[2-(4-fluorophenyl)-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino]-N-methyl-benzamide 
• 1420885-96-6 2-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 
• 1425795-27-2 C₂₃H₁₆F₄N₄O 
• 1420885-87-5 (2,5-difluorobenzyl)-[2-(4-fluorophenyl)-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-amine 
• 1420885-97-7 2-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine-7-oxide 
• 1420885-98-8 4-chloro-2-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]-pyridine 
• 1420885-99-9 4-chloro-2-(4-fluorophenyl)-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine 
• 1420885-95-5 3-((4-fluorophenyl)ethynyl)-5-(trifluoromethyl)pyridin-2-amine 
• 1036027-54-9 5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 
• 1142192-57-1 3-iodo-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

HETEROCYCLIC COMPOUND

The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors

Focal adhesion kinase (FAK) is considered as an attractive target for oncology, and small-molecule inhibitors are reported to be in clinical testing. In a surface plasmon resonance (SPR)-mediated fragment screening campaign, we discovered bicyclic scaffolds like 1H-pyrazolo[3,4-d]pyrimidines binding to the hinge region of FAK. By an accelerated knowledge-based fragment growing approach, essential pharmacophores were added. The establishment of highly substituted unprecedented 1H-pyrrolo[2,3-b]pyridine derivatizations provided compounds with submicromolar cellular FAK inhibition potential. The combination of substituents on the bicyclic templates and the nature of the core structure itself have a significant impact on the compounds FAK selectivity. Structural analysis revealed that the appropriately substituted pyrrolo[2,3-b]pyridine induced a rare helical DFG-loop conformation. The discovered synthetic route to introduce three different substituents independently paves the way for versatile applications of the 7-azaindole core.

Spirocyclic Azaindole Derivatives

The invention relates to substituted azaindole derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted azaindole derivatives for producing medicaments.

NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7

The present invention relates to imidazolone derivatives of formula (I) to methods of preparing such derivatives, intermediates thereto, pharmaceutical compositions comprising such derivatives, and methods of inhibiting protein kinase, and methods of treatment comprising administration of such derivatives.

Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof

The invention relates to compounds of formula (I): Wherein n, the pyrrolopyridine core, X, Y and W are as described herein. The invention also relates to a preparation method and to a therapeutic application.

5-CYAN0-4- (PYRROLO [2, 3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The invention concerns compounds of general formula (I), wherein n, the pyrrolopyridine ring, X, Z1, Z2, Z3, Z4, Z5 and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.

N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.